Sepsis, a complication of an infection caused by foreign cells infiltrating a person’s bloodstream, affects nearly two million people each year in the U.S. If not addressed quickly, the infection triggers the body’s immune system to begin attacking its own organs, resulting in a slow, weeks-long death. The challenge for clinicians is identifying the source […]
T2 Biosystems prices $46m offering
T2 Biosystems today priced an upcoming $45.8 million offering, looking to float approximately 6.1 million shares. In the offering, T2 Biosystems will offer shares at a price of $7.50 per share, slightly lower than the May 29 closing price of $8.06 per share. As of 11:11 a.m. EDT, T2 Biosystems shares are trading at $8.34 pre […]
T2 Biosystems wins FDA nod for T2 Bacteria panel, plans offering
T2 Biosystems today announced it won FDA clearance for its T2 Bacteria panel for detecting bacterial species in human blood from patients with suspected bloodstream infections, and announced plans for an upcoming offering. The Lexington, Mass.-based company said that it won approval for the detection of specific sepsis-causing bacterial pathogens as acquired from a whole […]
T2 Biosystems touts results from 4 studies of its T2Dx diagnostics system
T2 Biosystems this week released results from four studies of its T2Dx blood diagnostics system designed to detect pathogens that cause sepsis, touting clinical and performance advantages when compared to traditional blood cultures. The four studies were published in the Journal of Antimicrobial Chemotherapy, the Lexington, Mass.-based company said. A study conducted at Rome’s Gemelli Hospital […]
T2 Biosystems lands $2m grant for ‘superbug’ test
T2 Biosystems won a $2 million grant to develop a test using its T2Dx MR-based technology to detect strains of drug-resistant bacteria or so-called “superbugs.” The grant is from Carb-X, a Boston University-based public-private partnership aimed at furthering anti-bacterial R&D that’s jointly funded by the U.S. Health & Human Services Dept.’s Biomedical Advanced Research & Development […]
T2 Biosystems tops The Street with Q4, 2017 earnings
T2 Biosystems Inc. (NSDQ:TTOO) today reported fourth quarter and full year 2017 earnings that topped expectations on Wall Street. The Lexington, Mass.-based company reported sales of $1.7 million for its fourth quarter, up 87% when compared with the same quarter least year. Costs for the quarter, excluding the cost of product revenue, were $9.8 million, down […]
InVivo Therapeutics lifts Toselli to permanent prez, CEO | Personnel Moves February 6, 2018
InVivo Therapeutics (NSDQ:NVIV) said yesterday it made Dr. Richard Toselli’s spot in the corner office permanent, lifting him from acting CEO to prez and CEO. Dr. Toselli will maintain his position on the company’s board and as its chief medical officer, the position he was given when he joined the company last July. Prior to joining InVivo, […]
T2 Biosystems prices $18m offering
T2 Biosystems Inc. (NSDQ:TTOO) last week priced a public offering looking to raise $17.5 million. The Lexington, Mass.-based company said it is offering 4.4 million shares of its common stock at $4 per share with a 30-day underwriters option to purchase an additional 656,250 shares at the same price. T2 Biosystems said it expects the offering […]
T2 Biosystems files 510(k) for T2Bacteria Panel
T2 Biosystems Inc. (NSDQ:TTOO) said today it filed a 510(k) appliation with the FDA for its T2Bateria Panel rapid diagnostic solution designed to identify pathogens assocaited with Sepsis. The T2Bacteria panel is designed to run on the FDA-cleared T2Dx instrument to provide diagnosis of sepsis pathogens within hours, reducing the time for patients with bloodstream infections […]
CDC to use T2 Biosystems in testing for superbug Candida auris
T2 Biosystems Inc. (NSDQ:TTOO) said today that the US Centers for Disease Control and Prevention will use its T2Dx Instrument to test and monitor for the emergence and outbreaks of the antibiotic-resistant superbug Candida auris. The Lexington, Mass.-based company said the use of the T2Dx “represents multiple, new applications” for the platform. The system will be […]
T2 Biosystems wins CE Mark for MR-based bacteria detector, closing in on FDA bid
T2 Biosystems Inc. (NSDQ:TTOO) said today it won CE Mark approval in the European Union for its T2Bacteria Panel magnetic resonance-based bacterial detector, and said that it has entered the final stages of its FDA pivotal trial as it seeks 510(k) approval from the agency. The T2Bacteria Panel is designed to run on the company’s T2Dx […]
- 1
- 2
- 3
- 4
- Next Page »
MassDevice Network
@MassDevice
LinkedIn
YouTube